Cocrystal Pharma Inc
The COCP stock trades on Nasdaq All Markets
Company Description
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.
Technology
Our proprietary structural biology, enzymology and medicinal chemistry expertise enable us to develop novel antiviral agents. These technologies and our market-focused approach to drug discovery are designed to effectively create small molecule therapeutics that are safe, effective and convenient to administer. Our unique structure-based drug discovery platform provides a 3-D structure of inhibitor complexes at near-atomic resolution and immediate insight to guide Structure Activity Relationships (SAR). This helps us identify novel binding sites and allows for a rapid turnaround of structural information through highly automated x-ray data processing and refinement.
Drug Pipeline
Source: Cocrystal Pharma Inc - 20221108
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
CC-31244
Hepatitis C
Phase 2
CC-42344
Influenza A
Phase 1
CDI-45205
COVID-19
Preclinical
Influenza A/B Inhibitor
Influenza A/b
Preclinical
Replication and Protease Inhibitors
Norovirus Gastroenteritis
Preclinical
0 Comments on COCP stock
Newest
Conversation